Press Release

Nextech Invest New Portfolio Company Kura Oncology Raises US$ 60 million, Signs Deal with Janssen and Completes Reverse Merger

Zurich (Switzerland), March 13, 2015 - Nextech Invest Ltd., the Swiss specialist cancer venture capital investor, today announced the successful completion of a US$ 60 million private placement in Kura Oncology (La Jolla, California, USA). In conjunction with the fund raising, the company also completed a reverse merger in the US and gained an exclusive license from Janssen Pharmaceutica NV to develop and commercialize tipifarnib in solid tumors driven by activating mutation in the oncogene HRAS and in patients with hematologic malignancies.

Kura Oncology has completed a private placement of its common stock to new institutional investors and existing investors that resulted in gross proceeds of approximately US$ 60 million to the company, including approximately US$ 7.5 million in bridge notes that converted into common stock at the closing. EcoR1 Capital was the lead investor in this financing, which included significant participation from Fidelity Management & Research Company, ARCH Venture Partners, Boxer Capital of Tavistock Life Sciences, Partner Fund Management as well as a number of other well-known healthcare investors. Proceeds from the private placement will be used for the development of the company's drug candidates, including tipifarnib, as well as preclinical pipeline programs.

"From an investors' perspective it is rare to have an opportunity as exciting as Kura Oncology," said Alfred Scheidegger, Founding Partner at Nextech Invest Ltd. "Licensing tipifarnib from Janssen Pharmaceutica provides an accelerated development path for Kura Oncology and the company's exceptional management team. Combining this with a very interesting preclinical pipeline sets the company well ahead of its peers," said Thilo Schroeder, Partner at Nextech Invest Ltd. This is the second investment from Nextech Invests' Oncology IV fund after investing in Peloton Therapeutics in October 2014. The Oncology IV fund had a first closing of US$ 40 million in September 2014 and is targeting a final close of US$ 100 million.

In conjunction with the private placement Kura Oncology reverse merged into Zeta Acquisition Corp III, a public reporting company with no prior business operations. Stockholders of Kura Oncology, including those that participated in the private placement, received shares of Zeta Acquisition in exchange for their Kura Oncology shares, and the former Kura Oncology stockholders now hold 100 percent of the resulting company's equity in the same proportion as the stockholders owned immediately following the private placement. Zeta Acquisition has been renamed Kura Oncology, Inc. and will implement the pre-merger business plan of Kura Oncology.

Nextech Invest currently holds nine companies in its portfolio all focusing on different cancer treatment approaches. The portfolio includes: kinase inhibitor company Blueprint Medicines; ImaginAb, an antibody fragment-based diagnostics imaging company; immunotherapy company MacroGenics; MolecularMD, a molecular diagnostics company; Peloton Therapeutics, a developer of therapies in kidney cancer; solid and hematologic cancer company Sunesis; Smac mimetics specialist Tetralogic; targeted therapy company TRACON Pharmaceuticals plus Kura Oncology. Over the last eight years Nextech Invest has made three trade sale exits, two partial exits and three IPOs.

About Nextech Invest Ltd.
The global oncology specialist venture capital firm Nextech Invest Ltd., established in 1998 in Zurich, Switzerland, focuses on investing in cancer companies. Supported by a Scientific Advisory Board of six oncologists chaired by Prof. Dr. David Livingston, Deputy Director Dana-Farber/Harvard Cancer Center, Nextech Invest is investing in emerging companies with pioneering innovations in cancer research that have compounds entering clinical trials. The other members of the Scientific Advisory Board are: Prof. Dr. Karl-Heinz Altmann, Prof. Dr. William Kaelin, Prof. Dr. Sir Bruce Ponder, Dr. Charles Sawyers and Prof. Dr. Paul Workman. Nextech Invest is a longstanding member of leading networks in private equity, such as SECA and EVPA. Nextech Invest works closely with the Union for International Cancer Control (UICC).

For more information, please contact:
Alfred Scheidegger
Nextech Invest Ltd.
PhD, Founding Partner & CEO
Tel.: +41 44 366 66 12
scheidegger@nextechinvest.com
www.nextechinvest.com

Nextech IV Oncology S.C.S. SICAV-SIF (the "Partnership") is established under the laws of the Grand Duchy of Luxembourg and compliant for distribution to qualified investors in Switzerland. The Swiss representative is Carnegie Fund Services SA, 11, rue du Général-Dufour, 1204 Geneva. The Swiss paying agent is Banque Cantonale de Genève, 17, quai de l'Ile, 1204 Geneva. Qualified investors can obtain the Issuing Document, the Limited Partnership Agreement, as well as the annual reports for the Partnership and the un-audited quarterly investor reports free of charge from the Swiss representative.